Neuro Vigor and University of Western Australia announce collaborative drug development agreement

0

The focus will be on new chemical entities to neutralize reactive aldehydes associated with multiple inflammatory and traumatic diseases

HAMMOND, Ind. – Neuro Vigor, a Purdue University-affiliated biotechnology company developing drugs that neutralize reactive aldehydes, announced on Tuesday (October 26) a collaboration agreement with the University of Western Australia jointly develop proprietary drugs to initially target neurodegenerative diseases and pain in spinal cord injury, or SCI.

Reactive aldehydes are highly toxic molecules released by cells in response to external or internal stress and trauma. They significantly increase in inflammatory, neurotraumatic and neurodegenerative disease states, damaging tissue at the cellular and molecular levels, perpetuating a destructive cycle of inflammation and oxidative stress.

“This agreement launches the science and technology needed to provide relief to patients with neuropathic pain or neurodegenerative diseases,” said Mark Van Fleet, CEO of Neuro Vigor. “It combines Neuro Vigor’s understanding of preclinical neurobiology and the importance of neutralizing reactive aldehydes with the discovery by the University of Western Australia of new drug compounds that have exciting clinical promise.”

From a group of compounds identified by researchers at the University of Western Australia, the partners will initially assess preclinical reactive aldehyde scavengers, which have the best potential as therapeutic agents to curb pathology in multiple diseases, including SCI neuropathic pain.

The first stage of the two-year joint R&D effort will be funded by grants to Neuro Vigor by the Indiana Spinal Cord and Brain Injury Fund and the University of Western Australia. Under the agreement, the university grants Neuro Vigor an exclusive option to license the resulting intellectual property of chemical entities resulting from the collaboration.

“We are delighted to have partnered with Neuro Vigor and look forward to seeing this collaboration grow,” said Dr Louis Pymar, Senior Marketing Manager at the University of Western Australia.

“Neurodegenerative diseases and spinal cord injuries present significant unmet medical needs, and we hope this discovery may lead to new, differentiated treatment options. “

About Neuro Vigor

Neuro Vigor, a company affiliated with Purdue University, is pioneering the development of drugs to scavenge reactive aldehydes at a dosage and formulation targeted to the conditions in which the aldehydes play a central role. The company’s first clinical priority is the treatment of neuropathic pain in spinal cord patients for whom current care is inadequate. Neuro Vigor’s search for more effective pain treatments with fewer side effects is also supported by the National Institute of Health’s Helping to End Addiction Long-term initiative (Helping to End Addiction Long-term), which supports research aimed at improving management. pain and treatment for opioid abuse and dependence.

About the University of Western Australia

The University of Western Australia (UWA) is one of Australia’s leading research-intensive universities in the top 1% of world universities on the Shanghai Jiao-Tong Academic Ranking of World Universities (ARWU). This collaboration with Neuro Vigor is led by Associate Professor Phil Burcham of the UWA School of Allied Health and School of Biomedical Sciences, as well as Associate Professor Matt Piggott of the School of Molecular Sciences.

Contacts:

Neuro Vigor: Mark Van Fleet, [email protected]

University of Western Australia: Dr Louis Pymar, [email protected]

Purdue Research Foundation: Steve Martin, [email protected]


Source link

Leave A Reply

Your email address will not be published.